Barbara Mazzi

Livorno, 57121, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Treatment with Kinase Inhibitors Plus Myo-Inositol as Re-Differentiating Agents in Iodine-Refractory Thyroid Cancers.

Treatment with Kinase Inhibitors Plus Myo-Inositol as Re-Differentiating Agents in Iodine-Refractory Thyroid Cancers.

Journal: Life (Basel, Switzerland)

Published: January 14, 2026

Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.

Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.

Journal: Journal of endocrinological investigation

Published: June 13, 2020

Choroidal vascularity index in thyroid-associated ophthalmopathy: a cross-sectional study.

Choroidal vascularity index in thyroid-associated ophthalmopathy: a cross-sectional study.

Journal: Eye and vision (London, England)

Published: June 02, 2020

Retinal, choroidal and optic disc analysis in patients with Graves' disease with or without orbitopathy.

Retinal, choroidal and optic disc analysis in patients with Graves' disease with or without orbitopathy.

Journal: International ophthalmology

Published: January 08, 2020

Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.

Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.

Journal: Journal of endocrinological investigation

Published: July 26, 2018

Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.

Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.

Journal: Journal of endocrinological investigation

Published: May 22, 2018

High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study.

High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study.

Journal: Thyroid : official journal of the American Thyroid Association

Published: January 17, 2018

Rehabilitative orbital decompression for Graves' orbitopathy: results of a randomized clinical trial.

Rehabilitative orbital decompression for Graves' orbitopathy: results of a randomized clinical trial.

Journal: Journal of endocrinological investigation

Published: November 29, 2017

Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.

Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.

Journal: Journal of endocrinological investigation

Published: July 03, 2017

Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.

Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.

Journal: European thyroid journal

Published: April 07, 2017

VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.

VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Published: October 13, 2016

Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.

Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.

Journal: Journal of endocrinological investigation

Published: July 05, 2016

Showing 1-12 of 19

Last Updated: 09/26/2026